13F Holdings
中文EN

DNTH Dianthus Therapeutics, Inc. /DE/

Pharmaceutical Preparations · Nasdaq · SEC CIK 1690585 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-67.3%
TTM net income YoY-91.1%
TTM EPS YoY-64.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,739.3%
Net margin-7,973.3%
FCF margin-6,349.4%
EBITDA margin-8,733.9%

Returns

ROE-38.4%
ROA-35.9%
ROIC (approx.)-36.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets7.1%
Debt / equity0.00x
Current ratio13.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue10.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$284,000$396,000$193,000$1.16M$1.33M
R&D expense$45.60M$48.69M$34.53M$59.90M$32.49M$26.25M$27.00M$26.41M
SG&A expense$14.08M$13.56M$12.47M$9.93M$8.20M$8.87M$7.34M$6.83M
Operating income-$58.47M-$61.48M-$46.53M-$69.54M-$40.29M-$34.93M-$33.18M-$31.92M
Net income-$46.64M-$50.22M-$40.83M-$64.43M-$36.77M-$31.63M-$29.51M-$28.44M
EBITDA-$58.44M-$61.45M-$46.50M-$69.51M-$40.26M-$34.90M-$33.15M-$31.89M
EPS (basic)-0.81-0.90-0.85—-0.97-0.88-0.82—
EPS (diluted)-0.81-0.90-0.85—-0.97-0.88-0.82—
Dividends declared per share0.000.000.000.000.000.000.000.00
Weighted avg. shares (diluted)57.34M56.03M48.03M—37.79M35.82M35.79M—
Balance sheet
Cash & equivalents$55.69M$110.55M$627.67M$51.09M$55.98M$13.24M$10.12M$23.02M
Short-term investments$782.10M$776.26M$483.59M$353.21M$346.63M$244.15M$253.11M$252.45M
Receivables$582,000$106,000$1.23M$52,000$5.00M$39,000$1.00M$0
Current assets$856.04M$897.54M$1.12B$409.44M$413.82M$263.61M$271.00M$280.90M
PP&E, net$749,000$418,000$274,000$296,000$185,000$207,000$191,000$194,000
Total assets$1.28B$1.21B$1.25B$530.92M$577.45M$326.08M$348.58M$374.01M
Current liabilities$28.52M$34.39M$38.28M$30.73M$23.86M$20.09M$16.95M$18.45M
Total liabilities$34.82M$41.25M$45.57M$37.52M$30.99M$23.00M$19.97M$21.53M
Shareholders' equity$1.24B$1.17B$1.20B$493.40M$546.45M$303.08M$328.61M$352.48M
Shares outstanding56.30M54.80M54.58M43.22M42.85M32.18M32.13M31.12M
Cash flow statement
Operating cash flow-$50.33M-$48.98M-$28.86M-$46.98M-$30.55M-$23.89M-$27.63M-$27.44M
Capital expenditure$368,000$181,000$10,000$138,000$5,000$46,000$24,000$31,000
Free cash flow-$50.70M-$49.16M-$28.87M-$47.12M-$30.56M-$23.94M-$27.65M-$27.48M
Investing cash flow-$111.87M-$478.52M-$133.97M$37.20M-$201.28M$26.45M$14.79M-$23.11M
Financing cash flow$107.47M$10.38M$739.41M$4.88M$274.51M$568,000$161,000$39.68M
Depreciation & amortization$37,000$37,000$32,000$27,000$27,000$30,000$27,000$26,000
Stock-based compensation$12.72M$11.90M$10.60M$5.98M$5.79M$5.71M$5.32M$3.92M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.